MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13058-025-02020-x

Медицинская библиотека · Breast cancer research : BCR · 2025

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.

Venetis Konstantinos, Cursano Giulia, Scafetta Roberta, Giachetti Pier Paolo Maria Berton, Concardi Alberto, De Camilli Elisa, D'Ercole Marianna, Mane Eltjona, Frascarelli Chiara, Marra Antonio, Gandini Sara, Pepe Francesco, Scagnoli Simone, Rossi Silvia Maria, Troiano Raffaella, Speziale Elena, De Angelis Carmine, Troncone Giancarlo, Malapelle Umberto, Perrone Giuseppe, Botticelli Andrea, Viale Giuseppe, Curigliano Giuseppe, Guerini Rocco Elena, Criscitiello Carmen, Fusco Nicola

СтатьяПеревод пока не подготовлен

Аннотация

Mutations in ESR1 play a critical role in resistance to endocrine therapy (ET) in hormone receptor-positive (HR +)/HER2- metastatic breast cancer (MBC). Testing for ESR1 mutations is essential for guiding treatment with novel oral selective estrogen receptor degraders (SERDs) like elacestrant or camizestrant. While most studies have utilized liquid biopsy (LB) for mutation detection, the role of formalin-fixed paraffin-embedded (FFPE) tissue biopsy in this context remains unclear. In this study, we analyzed a cohort of HR + /HER2- MBC patients who experienced resistance to ET and CDK4/6 inhibitors. Next-generation sequencing (NGS) was performed on FFPE biopsy samples obtained from metastatic sites at the time of disease progression. ESR1 mutations were detected in 24 out of 38 patients (63.2%), with p.D538G identified in 10 patients (45.5%) and p.Y537S in 6 patients (27.2%) as the most frequent alterations. One patient exhibited dual ESR1 mutations, and a recurrent ESR1-CCDC170 gene fusion was identified, underscoring the diversity and potential interplay of genetic alterations driving resistance in HR + /HER2- MBC. Notably, lung metastases were significantly more common in ESR1 mutant cases (8/24, 33.3%) compared to wild-type cases (1/14, 7.1%), while liver metastases showed no difference between mutant (12/24, 50.0%) and wild-type groups (7/14, 50.0%). Co-mutations in actionable pathways, particularly PIK3CA, were observed in n = 10 ESR1 mutant tumors (41.6%), highlighting their contribution to resistance mechanisms and posing significant challenges for treatment selection, as these alterations may necessitate combination therapies to effectively target multiple resistance pathways. This study presents new insights into the prevalence and clinical significance of ESR1 mutations in HR + /HER2- MBC, highlighting the potential utility of FFPE biopsy samples as a viable alternative or complementary approach to LB for mutation detection, particularly in resource-limited settings where access to ctDNA analysis may be constrained.

Для цитирования: Venetis Konstantinos, Cursano Giulia, Scafetta Roberta, Giachetti Pier Paolo Maria Berton, Concardi Alberto, De Camilli Elisa, D'Ercole Marianna, Mane Eltjona, Frascarelli Chiara, Marra Antonio, Gandini Sara, Pepe Francesco, Scagnoli Simone, Rossi Silvia Maria, Troiano Raffaella, Speziale Elena, De Angelis Carmine, Troncone Giancarlo, Malapelle Umberto, Perrone Giuseppe, Botticelli Andrea, Viale Giuseppe, Curigliano Giuseppe, Guerini Rocco Elena, Criscitiello Carmen, Fusco Nicola. ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.. Breast cancer research : BCR. 2025. DOI: 10.1186/s13058-025-02020-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.